Phase III Study of Second-Line Chemotherapy for Advanced Non–Small-Cell Lung Cancer With Weekly Compared With 3-Weekly Docetaxel - Concepedia

Concepedia

Publication | Closed Access

Phase III Study of Second-Line Chemotherapy for Advanced Non–Small-Cell Lung Cancer With Weekly Compared With 3-Weekly Docetaxel

181

Citations

19

References

2005

Year

Wolfgang Schuette, S. Nagel, Thomas Blankenburg, Christine Lautenschlaeger, K. Hans, Ernst-Wilhelm Schmidt, Ina Dittrich, H Schweisfurth, Ludwig Fischer von Weikersthal, Aruna Raghavachar,

Journal of Clinical Oncology

Abstract

Weekly docetaxel 35 mg/m2 demonstrated similar efficacy and better tolerability than standard 3-weekly docetaxel 75 mg/m2 and can be recommended as a feasible alternative second-line treatment option for patients with advanced NSCLC.

References

	Year	Citations

Page 1